Identifying the Causality Relationship between Health Expenditure and Economic Growth: An Application on E7 Countries

Hasan DİNÇER¹
Serhat YÜKSEL²

ABSTRACT
This study aims to identify the causality relationship between health expenditure and economic growth in emerging economies. Within this framework, E7 countries are evaluated by using Pedroni panel cointegration method and Dumitrescu Hurlin panel causality analysis. For this purpose, annual data for the years between 1996 and 2016 is considered. As a result of Pedroni panel cointegration test, it is defined that there is a long run relationship between economic growth with total health expenditure and public health expenditure, but this relationship is not valid between private health care expenditure and economic growth. According to Dumitrescu Hurlin panel causality analysis results, it is concluded that there is not a causality relationship from the health expenditure to the economic growth. However, it is also determined that economic growth is the main cause of total, public and private health expenditure. Therefore, it is recommended that the role of private sector in health should be improved so that the health expenditure can have a positive contribution to the economic development of emerging countries.

Keywords: Health Expenditure, E7 Countries, Economic Growth, Pedroni Panel Cointegration Analysis, Dumitrescu Hurlin Panel Causality Analysis.

¹ İstanbul Medipol University, Turkey
² Health Systems and Policies Research Center, İstanbul Medipol University, Turkey,
Corresponding author: S. Yüksel, syuksel@medipol.edu.tr
INTRODUCTION

Economic growth is the most important purpose of the countries. The main reason of this issue is that it explains the development of these countries. In other words, when economic growth increases, it means that production of the goods and services in this country goes up as well (Barro, 1991). Another important point of economic growth is that it is a very significant indicator of the economy of the country on the eyes of foreign investors. Hence, foreign investors prefer to invest to the countries that have high economic growth. Because of this condition, countries aim to take many actions in order to provide economic growth (Acemoğlu and Restrepo, 2017; Lisowsky et. al., 2017).

Health expenditure is the factor that shows the life quality of people. Since the health is an essential issue in the lives of the people, any expenditure that contributes to people’s health has a positive influence on the welfare (Grigoli and Kapsoli, 2018). Therefore, it is accepted as the important aspect which gives information about the development of a country. Due to this condition, each country in the world aims to increase health expenditure (Stubbs et. al., 2017; Yip et. al., 2017). Within this framework, some governments make public health expenditure whereas some other countries try to attract the attention of private investors.

The relationship between economic growth and health care expenditure is a much-discussed topic in the literature. Most of the authors argue that health expenditure has a contribution to the economic improvement (Piabuo and Tieguhong, 2017; Erçelik, 201; Naidu and Chand, 2013). On the other hand, some researchers also believe that the countries, which have high economic growth, make more health expenditure (Wang et. al., 2018; Khoshnevis Yazdi and Khanalizadeh, 2017). In addition to them, the bidirectional relationship between these two different variables is also underlined (Mukherjee, 2017; Khan et. al., 2016). Moreover, some researchers also emphasize the importance of public health expenditure on economic improvement of the countries (Ghanbari and Basakha, 2008; Odior, 2011). Thus, it can be said that the studies that focus on this topic are very important in economic development of the countries.

Emerging countries refer to the countries that have not been developed yet.
Nevertheless, it is thought that they have a potential to grow (Karwowski and Stockhammer, 2017). Due to this situation, these countries try to take some actions in order to achieve this objective. For example, these countries may provide some incentives to the foreign investors to attract their attention (Armanios et. al., 2017). Thus, it can be possible to have economic development by increasing investments and decreasing unemployment rate. Within this context, health expenditure also plays a key role for this purpose because when the health level of the people goes up, they can be more productive (Jakovljevic et. al., 2017).

Parallel to the issues emphasized above, in this study, it is aimed to understand the causality relationship between economic growth and health expenditure. For this purpose, E7 countries are evaluated by using Pedroni panel cointegration method and Dumitrescu Hurlin panel causality analysis. In addition to these aspects, annual data for these variables between 1996 and 2016 is used. Also, in this process, the effects of public and private expenditure on economic development are taken into the consideration. As a result of this analysis, it can be possible to present recommendations that have a contribution to the development of emerging countries.

This study consists of 5 different sections. After the introduction part, some quantitative information about the health expenditure is given in the second part. In this section, the difference in health expenditure between different regions is shared. Moreover, the third part focuses on the details of similar studies in the literature. Therefore, it is aimed to identify the missing area in the literature related to this topic. Furthermore, in the fourth section, an application on E7 countries is given by using Pedroni panel cointegration method and Dumitrescu Hurlin panel causality analysis. Finally, recommendations are presented on the final part.

**QUANTITATIVE INFORMATION ABOUT HEALTH EXPENDITURE**

Health expenditure is accepted as a significant indicator of economic development. Hence, countries aim to increase the amount of this expenditure. Figure 1 illustrates the trends in current health expenditure in the world in the last decade.
Figure 1: Current Health Expenditure per Capita in US$

Source: World Health Organization (WHO)

Figure 1 gives information that current health expenditure has an increasing trend in last 10 years. This situation shows that most of the countries all around the world give importance to the health expenditure. For example, while the average of current health expenditure per capita was 345$ in 2000, this amount jumped to the amount of 822$ in 2015. In addition to this aspect, Figure 2 shows the changes in the domestic and external health expenditure.

Figure 2: Domestic and External Health Expenditure as % of Current Health Expenditure

Source: WHO

Figure 2 states that there is not a significant change in the ratio of domestic and external health expenditure. Another important point in this figure is that domestic health expenditure has a very high percentage in comparison with external health expenditure. Figure 3 demonstrates the percentage of government and private health expenditure in the last years.

Figure 3: Government and Private Health Expenditure as % of Current Health Expenditure

Source: WHO

Figure 3 states that there is not a significant change in the ratio of government and private health expenditure. Another important point in this figure is that government health expenditure has a very high percentage in comparison with private health expenditure.
and external health expenditure. Another important point in this figure is that domestic health expenditure has a very high percentage in comparison with external health expenditure. Figure 3 demonstrates the percentage of government and private health expenditure in the last years.

**Figure 3:** Government and Private Health Expenditure as % of Current Health Expenditure

Source: *WHO*

Figure 3 indicates that domestic government health expenditure is greater than domestic private health expenditure. In addition to this condition, it can also be seen that there is an increase in this difference especially in the last years. Figure 4 illustrates the total health expenditure for selected regions in the world as the percentage of GDP.

**Figure 4:** Total Health Expenditure of Selected Regions (% of GDP)

Source: *World Bank*
Figure 4 explains that the United States has the highest health expenditure ratio all around the world. Additionally, Euro area has also high percentage in comparison with other areas. On the other side, less developed countries and Africa have very low health expenditure percentage. While looking at this information, it can be understood that health expenditure percentage of GDP has a positive correlation with the income level of the countries.

**LITERATURE REVIEW**

The relationship between health expenditure and economic growth is evaluated by many different studies in the literature. Some selected studies are demonstrated in Table 1.

**Table 1: Selected Studies in the Literature**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Scope</th>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carrin and Politi (1996)</td>
<td>Least Developed Countries</td>
<td>Regression</td>
<td>The level of economic growth is an important indicator of health expenditure.</td>
</tr>
<tr>
<td>Leidl (1998)</td>
<td>European Countries</td>
<td>Granger Causality Analysis</td>
<td>Health care expenditure and economic growth affect each other significantly.</td>
</tr>
<tr>
<td>Mojtahed and Javadipour (2004)</td>
<td>Developing Countries</td>
<td>Regression</td>
<td>It is concluded that health expenditure contributes to economic development.</td>
</tr>
<tr>
<td>Chang and Ying (2006)</td>
<td>15 OECD Countries</td>
<td>Descriptive Statistics</td>
<td>It is identified that there is a positive correlation between economic development and health care expenditure.</td>
</tr>
<tr>
<td>Haldar (2008)</td>
<td>India</td>
<td>Granger Causality Analysis</td>
<td>There is two-way causality relationship between economic growth and health care expenditure.</td>
</tr>
<tr>
<td>Bukenya (2009)</td>
<td>US</td>
<td>VAR Model</td>
<td>There is a positive relationship between health care expenditure and economic development.</td>
</tr>
<tr>
<td>Emadzadeh et. al. (2011)</td>
<td>Developing Countries</td>
<td>Regression</td>
<td>Health care has a positive effect on economic growth.</td>
</tr>
<tr>
<td>Balaji (2011)</td>
<td>India</td>
<td>Granger Causality Analysis</td>
<td>When there is an economic growth, the health care expenditure increases.</td>
</tr>
<tr>
<td>Author(s) and Year</td>
<td>Country</td>
<td>Method</td>
<td>Findings/Notes</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------</td>
<td>--------</td>
<td>----------------</td>
</tr>
<tr>
<td>Wang (2011)</td>
<td>31 Different Countries</td>
<td>VECM Model</td>
<td>It is defined that health care expenditure has a positive influence on economic development.</td>
</tr>
<tr>
<td>Mehrara and Musai (2011)</td>
<td>Iran</td>
<td>Granger Causality Analysis</td>
<td>GDP growth is accepted as the significant cause of health expenditure.</td>
</tr>
<tr>
<td>Ogundipe and Lawal (2011)</td>
<td>Nigeria</td>
<td>Regression</td>
<td>Health care investment is the way of improving the economy.</td>
</tr>
<tr>
<td>Bakare and Olubokun (2011)</td>
<td>Nigeria</td>
<td>Regression</td>
<td>There is a positive relationship between health care expenditure and economic growth.</td>
</tr>
<tr>
<td>Luo (2011)</td>
<td>China</td>
<td>Data Envelopment Analysis</td>
<td>Public health expenditure has a positive influence on economic improvement.</td>
</tr>
<tr>
<td>Keehan et al. (2012)</td>
<td>US</td>
<td>Descriptive Statistics</td>
<td>National health expenditure has a positive influence on economic growth.</td>
</tr>
<tr>
<td>Nasiru and Usman (2012)</td>
<td>Nigeria</td>
<td>ARDL</td>
<td>There is bidirectional relationship between health care and economic development.</td>
</tr>
<tr>
<td>Odubunmi et al. (2012)</td>
<td>Nigeria</td>
<td>Johansen Cointegration Analysis</td>
<td>Health expenditure has a strong effect on economic improvement.</td>
</tr>
<tr>
<td>Cylus et al. (2012)</td>
<td>24 European Countries</td>
<td>Descriptive Statistics</td>
<td>In case of economic recession, health care expenditure decreases.</td>
</tr>
<tr>
<td>Naidu and Chand (2013)</td>
<td>Pacific Island Countries</td>
<td>Regression</td>
<td>Health care expenditure is an important factor to have economic improvement.</td>
</tr>
<tr>
<td>Saftari et al. (2013)</td>
<td>Iran</td>
<td>VAR</td>
<td>Health expenditure has a positive influence on economic growth.</td>
</tr>
<tr>
<td>Öztürk and Ada (2013)</td>
<td>European Countries</td>
<td>Johansen Cointegration Analysis</td>
<td>There is a bidirectional causality relationship between economic development of the countries and health expenditure.</td>
</tr>
<tr>
<td>Mehmood et al. (2014)</td>
<td>26 Asian Countries</td>
<td>Granger Causality Analysis</td>
<td>There is a causality relationship from economic growth to the health expenditure.</td>
</tr>
<tr>
<td>Khan et al. (2016)</td>
<td>SAARC Countries</td>
<td>Kao Panel Cointegration Analysis</td>
<td>There is two-way correlation between economic improvement and health expenditure.</td>
</tr>
<tr>
<td>Halici-Tülüce et al. (2016)</td>
<td>44 Different Countries</td>
<td>GMM</td>
<td>There is a negative relationship between private health expenditure and economic growth.</td>
</tr>
<tr>
<td>Atılgan et al. (2017)</td>
<td>Turkey</td>
<td>ARDL Method</td>
<td>Health care expenditure has a significant contribution to the economic growth.</td>
</tr>
</tbody>
</table>
Developing Countries

Regression

Public health expenditure positively affects economic growth.

African Countries

GMM

Health expenditure is accepted as the significant indicator of economic growth.

India

VECM

It is concluded that health expenditure and economic growth affect each other.

MENA Countries

ARDL

Economic growth causes higher health expenditure.

Regression

Any increase in health care expenditure has a positive influence on economic growth.

24 Different Countries

Regression

In case of increase in health care expenditure, economic growth will be affected positively.

Turkey

ARDL

There is a significant relationship between health expenditure and economic development.

22 Different Countries

VAR

When economic growth decreases, it has a negative effect on health expenditure.

Table 1 shows that most of the studies focus on the impact of health expenditure on economic growth. For example, Wang and Lee (2018) conducted a study to analyze this relationship in 24 different countries. By using regression analysis, it is determined that health care expenditure has a significant contribution to the economic growth. Moreover, Piabuo and Tieguhong (2017), Naidu and Chand (2013), Bakare and Olubokun (2011), Ogundipe and Lawal (2011), Emadzadeh et. al. (2011) and Mojtabahed and Javadipour (2004) also reached the similar result by using the same methodology. Furthermore, Erçelik (2018) and Atlgan et. al. (2017) identified that health care expenditure has a positive influence on economic development with the help of ARDL methodology.

In addition to these studies, Bukenya (2009) tried to define the influence of health care expenditure on economic improvement of US. As a result of VAR analysis, it is concluded that health expenditure is accepted as the significant indicator of economic growth. Scheffler (2004) and Keehan et. al. (2012) also emphasized the same issue by using different methodology. Additionally, Wang (2011) focused on this relationship in 31 different countries. With the help of VECM, it is determined that health expenditure has a strong effect on economic improvement. Similarly, Chang and Ying (2006), Odubunmi et. al.
(2012), Safdari et. al. (2013) and Aboubacar and Xu (2017) also underlined the same situation for different countries, such as Iran and Nigeria.

By looking at Table 1, it can also be understood that some studies stated the opposite way of relationship between these variables. For instance, Wang et. al. (2018) aimed to identify this relationship in 22 different countries. By using VAR analysis, they determined that there is a causality relationship from economic growth to the health expenditure. Parallel to this study, Balaji (2011), Mehrara and Musai (2011) and Mehmood et. al. (2014) also reached this conclusion with the help of Granger causality analysis. Moreover, Carrin and Politi (1996), Cylus et. al. (2012) and Khoshnevis Yazdi and Khanalizadeh (2017) also identified that the level of economic growth is an important indicator of health expenditure.

Additionally, it is also seen that in some studies, mutual relationship between economic growth and health care expenditure is underlined. As an example, Mukherjee (2017) tried to define the relationship between these two variables in India. According to the VECM results, it is understood that there is a bidirectional causality relationship between economic development of the countries and health expenditure. Haldar (2008) also emphasized the similar aspect for the same country by using Granger causality analysis. Furthermore, Leidl (1998), Nasiru and Usman (2012), Öztürk and Ada (2013) and Khan et. al. (2016) are also other studies that showed the importance on two-way causality relationship between economic growth and health expenditure.

Moreover, it is also stated that some other studies made more specific analysis within this context. For instance, De Mendonça and Baca (2017) focused on 75 different developing economies by using regression analysis. They defined that public health expenditure positively affects economic growth. In addition to this study, Ghanbari and Basakha (2008), Odior (2011) and Luo (2011) also identified that public health expenditure has a positive influence on economic improvement. On the other hand, Halıcı-Tülüce et. al. (2016) conducted a study to evaluate the relationship between economic growth and health expenditure. With the help of GMM methodology, they concluded that there is a negative relationship between private health expenditure and economic growth.

While considering the studies emphasized in Table 1, it can be understood that the relationship between economic improvement and health care expenditure
attracted the attention of many different researchers. Owing to this aspect, many different studies were carried out for different countries. In addition to this condition, it can also be seen that different types of the methodology are also taken into the consideration, such as regression, VECM, Granger causality analysis and ARDL. Nevertheless, it is identified that there is a need for a new study in which the effects of public and private health expenditure on the economic growth are evaluated. Hence, making this kind of analysis with an original methodology makes a significant contribution to the literature.

AN EVALUATION ON E7 COUNTRIES
DATA AND SCOPE

In this study E7 countries are taken into the consideration. They are the biggest emerging economies, such as Brazil, China, India, Indonesia, Mexico, Russia, and Turkey. In the evaluation process, 3 different analyzes are performed to see the effect of total, public and private health expenditure on economic growth. The ratios of all health expenditures to the GDP are used. Moreover, with respect to the economic growth, annual GDP growth is considered. Annual data of these variables between the years 1996 and 2016 is used and this data is provided from the website of World Bank.

PEDRONI PANEL COINTEGRATION ANALYSIS

Cointegration analysis is used to understand whether there is a long-term relationship between the variables. In Pedroni panel cointegration analysis, there are 7 different tests which are Panel v-Statistic, Panel rho-Statistic, Panel PP-Statistic, Panel ADF-Statistic, Group rho-Statistic, Group PP-Statistic and Group ADF-Statistic. This methodology is suitable while making evaluation by using panel data. In this test, probability values of all these 7 tests are calculated. If the probability values of 4 or more tests are lower than 0.05, it means that there is cointegration between the variables. In other words, it can be said that these variables have long-run relationship (Pedroni, 2001; Pedroni, 1996).
DUMITRESCU HURLIN PANEL CAUSALITY ANALYSIS

Dumitrescu Hurlin panel causality analysis is the methodology which aims to understand the causal relationship between the variables. It is accepted as the advanced version of Granger causality analysis. In this approach, it is possible to evaluate by using panel data. The equation of Dumitrescu Hurlin panel causality analysis is shown below.

\[ Y_{t,t} = a_t + \sum_{k=1}^{K} Y_{t-k} + \sum_{k=1}^{K} B^k X_{t-k} + \varepsilon_{t,t} \quad (1) \]

In this equation, X and Y represent the variables. Therefore, the aim of this methodology is to determine whether X is the main cause of Y. Furthermore, B is the coefficient of the variable and a is the constant term. Additionally, \( \varepsilon \) refers to the error term and K gives information about the optimal lag interval (Dumitrescu and Hurlin, 2012).

Dumitrescu Hurlin panel causality analysis is studied in many different studies. For example, Latif et. al. (2017), Paramati et. al. (2016) and Adali and Yüksel (2017) focused on the causality relationship between foreign direct investment and economic growth. In addition to these studies, Dinçer et. al. (2017), Hasanov et. al. (2017) and Kahia et. al. (2017) evaluated the causality relationship between economic growth and energy consumption. Moreover, the relationship between financial development and economic growth is emphasized by using Dumitrescu Hurlin panel causality analysis in many different studies (Aydın and Malcıoğlu, 2016; Salahuddin and Alam, 2016; Abubakar et. al., 2015). Khan et. al. (2016), Tunah (2018) and Amiri and Linden (2016) are the studies that used Dumitrescu Hurlin panel causality analysis in health sector.

ANALYSIS RESULTS FOR E7 ECONOMIES

In order to understand whether there is a long-term relationship between health expenditure and economic growth, panel cointegration model is used. Within this scope, firstly, panel unit root test is performed to see whether the variables are stationary or not. The details of Im, Pesaran and Shin panel unit root test are given on Table 2.
Table 2: Im, Pesaran and Shin Panel Unit Root Test Results

<table>
<thead>
<tr>
<th>Variables</th>
<th>Level Value (probability)</th>
<th>First Difference (probability)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Health Expenditure</td>
<td>0.4241</td>
<td>0.0000</td>
</tr>
<tr>
<td>Public Health Expenditure</td>
<td>0.4574</td>
<td>0.0000</td>
</tr>
<tr>
<td>Private Health Expenditure</td>
<td>0.1933</td>
<td>0.0001</td>
</tr>
<tr>
<td>Economic Growth</td>
<td>0.0615</td>
<td>0.0000</td>
</tr>
</tbody>
</table>

Table 2 gives information that level probability values of all 4 variables are higher than 0.05. It shows that these variables have unit roots. Therefore, the first differences of these variables are taken into the consideration, and it is seen that all new probability values are less than 0.05. It is identified that all variables become stationary in their first differences. While considering these aspects, it is concluded that unit root test results satisfy the precondition of panel cointegration analysis. After stationary analysis, Pedroni panel cointegration test is performed to define the relationship between these variables. The details of this test are demonstrated on Table 3.

Table 3: Pedroni Panel Cointegration Test Results

<table>
<thead>
<tr>
<th>Relationship Type</th>
<th>Test Name</th>
<th>Probability Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>The relationship between total health expenditure and economic growth</td>
<td>Panel v-Statistic</td>
<td>0.0365</td>
</tr>
<tr>
<td></td>
<td>Panel rho-Statistic</td>
<td>0.0000</td>
</tr>
<tr>
<td></td>
<td>Panel PP-Statistic</td>
<td>0.0000</td>
</tr>
<tr>
<td></td>
<td>Panel ADF-Statistic</td>
<td>0.0000</td>
</tr>
<tr>
<td></td>
<td>Group rho-Statistic</td>
<td>0.0021</td>
</tr>
<tr>
<td></td>
<td>Group PP-Statistic</td>
<td>0.0000</td>
</tr>
<tr>
<td></td>
<td>Group ADF-Statistic</td>
<td>0.0001</td>
</tr>
<tr>
<td>The relationship between public health expenditure and economic growth</td>
<td>Panel v-Statistic</td>
<td>0.4358</td>
</tr>
<tr>
<td></td>
<td>Panel rho-Statistic</td>
<td>0.1878</td>
</tr>
<tr>
<td></td>
<td>Panel PP-Statistic</td>
<td>0.0028</td>
</tr>
<tr>
<td></td>
<td>Panel ADF-Statistic</td>
<td>0.0093</td>
</tr>
<tr>
<td></td>
<td>Group rho-Statistic</td>
<td>0.6027</td>
</tr>
<tr>
<td></td>
<td>Group PP-Statistic</td>
<td>0.0009</td>
</tr>
<tr>
<td></td>
<td>Group ADF-Statistic</td>
<td>0.0167</td>
</tr>
<tr>
<td>The relationship between private health expenditure and economic growth</td>
<td>Panel v-Statistic</td>
<td>0.8921</td>
</tr>
</tbody>
</table>
Table 3 gives information that with respect to the relationship between total health expenditure and economic growth, the probability values of all 7 different tests are lower than 0.05. Therefore, it is determined that the null hypothesis of “no cointegration” is rejected. In other words, it can be seen that there is a long-run relationship between total health expenditure and economic growth for these countries. Moreover, as for the relationship between public health expenditure and economic growth, it can be understood that the probability values of 4 different tests are lower than 0.05 whereas for other 3 tests, these values are greater than 0.05. Hence, it is concluded that there is a long-run relationship between public health expenditure and economic growth.

In addition to these issues, regarding the relationship between private health expenditure and economic growth, it can be seen that probability values of all 7 different tests are higher than 0.05. While considering these results, the null hypothesis cannot be rejected. Thus, it is identified that there is not a long-run relationship between private health expenditure and economic growth. After making panel cointegration analysis, panel causality analysis is also performed by using Dumitrescu Hurlin methodology. The details of this analysis are explained in Table 4.

### Table 4: Dumitrescu Hurlin Panel Causality Analysis Results

<table>
<thead>
<tr>
<th>The Way of the Relationship</th>
<th>Lag</th>
<th>Probability Values</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Health Expenditure → Economic Growth</td>
<td>1</td>
<td>0.6304</td>
<td>Total health expenditure does not cause economic growth.</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.9158</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.4429</td>
<td></td>
</tr>
<tr>
<td>Economic Growth → Total Health Expenditure</td>
<td>1</td>
<td>0.0000</td>
<td>Economic growth is the main cause of total health care expenditure.</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.0000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.0000</td>
<td></td>
</tr>
</tbody>
</table>
Table 4 explains that there is not a causality relationship from the total health expenditure to the economic growth. The main reason is that the probability values of all lags are greater than 0.05. This situation is also similar with respect to the relationship from public health expenditure to the economic growth. Hence, the null hypothesis of “no causality relationship” cannot be rejected. Furthermore, as for the causality relationship from private health expenditure to the economic growth, the probability value for lag 1 (0.0003) is lower than 0.05. In spite of this situation, it can also be seen that the probability values for other lags are greater than 0.05. Hence, it can be said that private health expenditure does not cause economic growth.

Additionally, regarding the relationship from economic growth to the total health expenditure, it is defined that probability values of all lags are lower than 0.05. This situation indicates that the null hypothesis of “no causality relationship” can be rejected. Similar to this issue, all probability values are also lower than 0.05 with respect to the relationship from economic growth to the public and private health expenditure. Therefore, it can be concluded that in addition to the causality relationship between economic growth and total health expenditure, it can also be said that economic growth leads to higher public and private health expenditure for E7 countries.

**CONCLUSION**

Health expenditure plays a key role in the economic improvement of emerging economies. When people in these countries become healthier, they
can be more productive. Hence, it is believed that health expenditure has a contributing effect for emerging countries to reach the developed status. Because of this situation, many emerging countries try to take some actions so as to increase health expenditure. The main purpose behind this issue is to increase investment and decrease unemployment rate so that it can be possible to have economic development.

In this study, it is aimed to evaluate the relationship between economic growth and health expenditure in emerging economies. Within this context, E7 countries are examined by using Pedroni panel cointegration method and Dumitrescu Hurlin panel causality analysis. For this purpose, annual data for the years between 1996 and 2016 is considered to reach this objective. Moreover, two different additional analyses are also performed in order to identify whether public and private health care expenditure has an influence on economic improvement of these countries.

In the first process of the analysis, Im, Pesaran and Shin panel unit root test is performed to understand whether the variables are stationary or not. It is understood that level probability values of all 4 variables are higher than 0.05 and these values for the first difference of these variables are lower than 0.05. Hence, it is defined that variables become stationary in their first difference. Hence, it can be understood that panel unit root test results satisfy the precondition of panel cointegration analysis.

After stationary analysis, Pedroni panel cointegration test is performed to identify the relationship between these variables. Firstly, it is determined that the null hypothesis of “no cointegration” is rejected with respect to the relationship between total health expenditure and economic growth. It can also be seen that there is a long-run relationship between public health expenditure and economic growth. On the other side, it is identified that there is not a long-run relationship between private health care expenditure and economic growth.

According to Dumitrescu Hurlin panel causality analysis, it is concluded that there is not a causality relationship from the total health expenditure to the economic growth. Similarly, a significant causality relationship cannot be found between economic growth and public and private health care expenditure. On the other hand, it is determined that economic growth is the
main reason of total health expenditure, public health expenditure and private health expenditure.

By considering these results, it can be stated that health expenditure does not have a contributing influence on economic development of emerging countries. Nevertheless, it is concluded that when economic growth of these emerging countries increases, they can give more importance to health care expenditure. This situation is also underlined in many different studies in the literature (Carrin and Politi, 1996; Cylus et al., 2012; Khoshnevis Yazdi and Khanalizadeh, 2017).

In emerging economies, government health expenditure is greater than private health expenditure and this difference is growing especially in recent years. Therefore, according to these results, it can be recommended that the role of private sector in health should be increased. This study aims to make contribution to the literature by focusing on this important topic for emerging economies. However, it is thought that a new study that also covers developed economies is also very beneficial.

REFERENCES


Preparing the Manuscript

General Considerations

Manuscripts should be kept to a minimum length. Authors should write in clear, concise English, employing an editing service if necessary. For professional assistance with improving the English, figures, or formatting in the manuscript before submission please contact the editorial office by e-mail for suggestions.

The responsibility for all aspects of manuscript preparation rests with the authors. Extensive changes or rewriting of the manuscript will not be undertaken by the Editors.

It is best to use the fonts “Times” and “Symbol.” Other fonts, particularly those that do not come bundled with the system software, may not translate properly. Ensure that all special characters (e.g., Greek characters, math symbols) are present in the body of the text as characters and not as graphic representations. Be sure that all characters are correctly represented throughout the manuscript—e.g., 1 (one) and l (letter l), 0 (zero) and O (letter o).

All text (including the title page, abstract, all sections of the body of the paper, figure captions, scheme or chart titles, and footnotes and references) and tables should be in one file. Graphics may be included with the text or uploaded as separate files. Manuscripts that do not adhere to the guidelines may be returned to authors for correction.

Articles of all kind. Use page size A4. Vertically orient all pages. Articles of all kind must be double-spaced including text, references, tables, and legends. This applies to figures, schemes, and tables as well as text. They do not have page limitations but should be kept to a minimum length. The experimental procedures for all of the experimental steps must be clearly and fully included in the experimental section of the manuscripts.
Nomenclature. It is the responsibility of the authors to provide correct nomenclature. It is acceptable to use semisynthetic or generic names for certain specialized classes of compounds, such as steroids, peptides, carbohydrates, etc. In such a case, the name should conform to the generally accepted nomenclature conventions for the compound class. Chemical names for drugs are preferred. If these are not practical, generic names, or names approved by the World Health Organization, may be used.

Compound Code Numbers. Compounds widely employed as research tools and recognized primarily by code numbers may be designated in the manuscript by code numbers. Their chemical name or structure should be provided. Editors have the discretion of determining which code numbers are considered widely employed.

Trademark Names. Trademark names for reagents or drugs must be used only in the experimental section. Do not use trademark or service mark symbols.

Manuscript Organization

Title Page. Title: The title of the manuscript should reflect the purposes and findings of the work in order to provide maximum information in a computerized title search. Minimal use of nonfunctional words is encouraged. Only commonly employed abbreviations (e.g., DNA, RNA, ATP) are acceptable. Code numbers for compounds may be used in a manuscript title when placed in parentheses AFTER the chemical or descriptive name.

Authors’ Names and Affiliations: The authors’ full first names, middle initials, last names, and affiliations with addresses at the time of work completion should be listed.

Abstract and keywords. Articles of all types must have an abstract. The maximum length of the Abstract should be 400 words, organized in a findings-oriented format in which the most important results and conclusions are summarized. Code numbers may be used once in the abstract.

After the abstract, a section of Keywords has to be given. Be aware that the keywords, chosen according to the general concept, are very significant during searching and indexing of the manuscripts.

Introduction. The rationale and objectives of the research should be discussed in this section. The background material should be brief and relevant to the research described.

Methodology. Materials, synthetic, biological, demographic, statistical or experimental
The methods of the research should be given detailed in this section. The authors are free to subdivide this section in the logical flow of the study. For the experimental sections, authors should be as concise as possible in experimental descriptions. General reaction, isolation, preparation conditions should be given only once. The title of an experiment should include the chemical name and a bold Arabic identifier number; subsequently, only the bold Arabic number should be used. Experiments should be listed in numerical order. Molar equivalents of all reactants and percentage yields of products should be included. A general introductory section should include general procedures, standard techniques, and instruments employed (e.g., determination of purity, chromatography, NMR spectra, mass spectra, names of equipment) in the synthesis and characterization of compounds, isolates and preparations described subsequently in this section. Special attention should be called to hazardous reactions or toxic compounds. Provide analysis for known classes of assay interference compounds.

The preferred forms for some of the more commonly used abbreviations are mp, bp, °C, K, min, h, mL, μL, g, mg, μg, cm, mm, nm, mol, mmol, μmol, ppm, TLC, GC, NMR, UV, and IR. Units are abbreviated in table column heads and when used with numbers, not otherwise.

**Results and Discussion.** This section could include preparation, isolation, synthetic schemes and tables of data. The discussions should be descriptive. Authors should discuss the analysis of the data together with the significance of results and conclusions. An optional conclusions section is not required.

**Ancillary Information.** Include pertinent information in the order listed immediately before the references.

**PDB ID Codes:** Include the PDB ID codes with assigned compound Arabic number. Include the statement “Authors will release the atomic coordinates and experimental data upon article publication.”

**Homology Models:** Include the PDB ID codes with assigned compound Arabic number. Include the statement “Authors will release the atomic coordinates upon article publication.”

**Corresponding Author Information:** Provide telephone numbers and email addresses for each of the designated corresponding authors.
Present/Current Author Addresses: Provide information for authors whose affiliations or addresses have changed.

Author Contributions: Include statement such as “These authors contributed equally.”

Acknowledgment: Authors may acknowledge people, organizations, and financial supporters in this section.

Abbreviations Used: Provide a list of nonstandard abbreviations and acronyms used in the paper, e.g., YFP, yellow fluorescent protein. Do not include compound code numbers in this list.

Citing in the Text. For citations in the text, use the last name of the author(s) and the year of publication (e.g. for a single author (Aydin, 2018) / for two authors (Aydin and Ozen, 2018) / for three or more authors (Aydin et al., 2018)

References and Notes. The accuracy of the references is the responsibility of the author(s). List all authors; do not use et al. Provide inclusive page numbers. The APA style should be used consistently throughout the references. For more details, please follow the links below.

https://www.apastyle.org/

List submitted manuscripts as “in press” only if formally accepted for publication. Manuscripts available on the Web with a DOI number are considered published. For manuscripts not accepted, use “unpublished results” after the names of authors. Incorporate notes in the correct numerical sequence with the references. Footnotes are not used.

Tables. Tabulation of experimental results is encouraged when this leads to more effective presentation or to more economical use of space. Tables should be numbered consecutively in order of citation in the text with Arabic numerals. Footnotes in tables should be given italic lowercase letter designations and cited in the tables as superscripts. The sequence of letters should proceed by row rather than by column. If a reference is cited in both table and text, insert a lettered footnote in the table to refer to the numbered reference in the text. Each table must be provided with a descriptive title that, together with column headings, should make the table self-explanatory. Titles
and footnotes should be on the same page as the table. Tables may be created using a word processor’s text mode or table format feature. The table format feature is preferred. Ensure each data entry is in its own table cell. If the text mode is used, separate columns with a single tab and use a return at the end of each row. Tables may be inserted in the text where first mentioned or may be grouped after the references.

**Figures, Schemes/Structures, and Charts.** The use of illustrations to convey or clarify information is encouraged. Remove all color from illustrations, except for those you would like published in color. Illustrations may be inserted into the text where mentioned or may be consolidated at the end of the manuscript. If consolidated, legends should be grouped on a separate page(s). Include as part of the manuscript file.

To facilitate the publication process, please submit manuscript graphics using the following guidelines:

1. The preferred submission procedure is to embed graphic files in a Word document. It may help to print the manuscript on a laser printer to ensure all artwork is clear and legible.

2. Additional acceptable file formats are: TIFF, PDF, EPS (vector artwork) or CDX (ChemDraw file). If submitting individual graphic files in addition to them being embedded in a Word document, ensure the files are named based on graphic function (i.e. Scheme 1, Figure 2, Chart 3), not the scientific name. Labeling of all figure parts should be present and the parts should be assembled into a single graphic.

EPS files: Ensure that all fonts are converted to outlines or embedded in the graphic file. The document settings should be in RGB mode. **NOTE:** While EPS files are accepted, the vector-based graphics will be rasterized for production. Please see below for TIFF file production resolutions.

3. TIFF files (either embedded in a Word doc or submitted as individual files) should have the following resolution requirements:

   - Black & White line art: 1200 dpi
   - Grayscale art (a monochromatic image containing shades of gray): 600 dpi
   - Color art (RGB color mode): 300 dpi
- The RGB and resolution requirements are essential for producing high-quality graphics within the published manuscript.

- Most graphic programs provide an option for changing the resolution when you are saving the image. Best practice is to save the graphic file at the final resolution and size using the program used to create the graphic.

4. Graphics should be sized at the final production size when possible. Single column graphics are preferred and can be sized up to 240 points wide (8.38 cm.). Double column graphics must be sized between 300 and 504 points (10.584 and 17.78 cm’s). All graphics have a maximum depth of 660 points (23.28 cm.) including the caption (please allow 12 points for each line of caption text).

Consistently sizing letters and labels in graphics throughout your manuscript will help ensure consistent graphic presentation for publication.

**Image Manipulation.** Images should be free from misleading manipulation. Images included in an account of research performed or in the data collection as part of the research require an accurate description of how the images were generated and produced. Apply digital processing uniformly to images, with both samples and controls. Cropping must be reported in the figure legend. For gels and blots, use of positive and negative controls is highly recommended. Avoid high contrast settings to avoid overexposure of gels and blots. For microscopy, apply color adjustment to the entire image and note in the legend. When necessary, authors should include a section on equipment and settings to describe all image acquisition tools, techniques, and settings, and software used. All final images must have resolutions of 300 dpi or higher. Authors should retain unprocessed data in the event that the Editors request them.

**Specialized Data**

**Biological Data.** Quantitative biological data are required for all tested compounds. Biological test methods must be referenced or described in sufficient detail to permit the experiments to be repeated by others. Detailed descriptions of biological methods should be placed in the experimental section. Standard compounds or established drugs should be tested in the same system for comparison. Data may be presented as numerical expressions or in graphical form; biological data for extensive series of compounds should be presented in tabular form.
Active compounds obtained from combinatorial syntheses should be resynthesized and retested to verify that the biology conforms to the initial observation. Statistical limits (statistical significance) for the biological data are usually required. If statistical limits cannot be provided, the number of determinations and some indication of the variability and reliability of the results should be given. References to statistical methods of calculation should be included.

Doses and concentrations should be expressed as molar quantities (e.g., mol/kg, μmol/kg, M, mM). The routes of administration of test compounds and vehicles used should be indicated, and any salt forms used (hydrochlorides, sulfates, etc.) should be noted. The physical state of the compound dosed (crystalline, amorphous; solution, suspension) and the formulation for dosing (micronized, jet-milled, nanoparticles) should be indicated. For those compounds found to be inactive, the highest concentration (in vitro) or dose level (in vivo) tested should be indicated.

If human cell lines are used, authors are strongly encouraged to include the following information in their manuscript:

- the cell line source, including when and from where it was obtained;
- whether the cell line has recently been authenticated and by what method;
- whether the cell line has recently been tested for mycoplasma contamination.

**Confirmation of Structure.** Adequate evidence to establish structural identity must accompany all new compounds that appear in the experimental section. Sufficient spectral data should be presented in the experimental section to allow for the identification of the same compound by comparison.

List only infrared absorptions that are diagnostic for key functional groups. If a series contains very closely related compounds, it may be appropriate merely to list the spectral data for a single representative member when they share a common major structural component that has identical or very similar spectral features.

**Submitting the Manuscript**

**Communication and log in to Author's Module** All submissions to JHESP should be made by using Online Article Acceptance and Evaluation system on the journal web page.
Registration to System It is required to register into the Online Article Acceptance and Evaluation system (Journal Park) for the first time while entering by clicking “Create Account” button on the registration screen and the fill the opening form with real information. Some of the information required in form is absolutely necessary and the registration will not work if these fields are not completely filled.

Authors are expected to return to the entry screen and log on with their username and password for the submission. Please use only English characters while determining your username and password.

If you already registered into the journal park system and forget your password, you should click on “Forgot My Password” button and your username and password will be mailed to your e-mail in a short while.

Adding Article This process consists of several different steps beginning with the loading of the article into the system. Browse button is used to reach the article file, under the Upload tab. After finding the article you may click to Choose File and file will be attached.